Urinary metabolome of infants with colic treated with Lactobacillus reuteri DSM 17938: a pilot randomized trial.

IF 2.6 4区医学 Q2 Medicine

Minerva pediatrica Pub Date : 2024-06-01 Epub Date: 2021-01-13 DOI:10.23736/S2724-5276.20.06128-9

Francesco Savino, Vassilios Fanos, Antonio Noto, Deborah Biggio, Claudia Fattuoni, Luigi Barberini

{"title":"Urinary metabolome of infants with colic treated with Lactobacillus reuteri DSM 17938: a pilot randomized trial.","authors":"Francesco Savino, Vassilios Fanos, Antonio Noto, Deborah Biggio, Claudia Fattuoni, Luigi Barberini","doi":"10.23736/S2724-5276.20.06128-9","DOIUrl":null,"url":null,"abstract":"Background: Lactobacillus reuteri DSM 17938 is the only probiotic recommended for treatment of colicky infants, but its mechanism of action is not clear. The study aim was to examine urinary metabolomic fingerprint of colicky breastfed infants before and after 1 month of orally administered Lactobacillus reuteri DSM 17938 or placebo.Methods: This randomized, blinded, placebo-controlled clinical trial was carried out with a well-documented probiotic. Thirty-two infants were enrolled, 16 in the probiotic group and 16 in the placebo group. Urine samples were collected from each subject before starting supplementation and at the end of the study period. Metabolomic profiles were obtained using a gas chromatography/mass spectrometry instrument. Subsequently, to compare groups before and after probiotic supplementation, univariate and multivariate statistical analysis were performed.Results: In the L. reuteri treated group all metabolites for all class of nutrients (sugars, amino acids, carboxylic acids) resulted more abundant after the study period. The comparison with a control group (placebo treated), confirmed this effect on urines.Conclusions: The metabolomic analysis of urine samples from infants treated with L. reuteri DSM 17938 allowed to detect some interesting features related to the effect of this treatment on urinary metabolome. To validate the results, a test on a larger cohort is required.","PeriodicalId":18533,"journal":{"name":"Minerva pediatrica","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva pediatrica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2724-5276.20.06128-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lactobacillus reuteri DSM 17938 is the only probiotic recommended for treatment of colicky infants, but its mechanism of action is not clear. The study aim was to examine urinary metabolomic fingerprint of colicky breastfed infants before and after 1 month of orally administered Lactobacillus reuteri DSM 17938 or placebo.

Methods: This randomized, blinded, placebo-controlled clinical trial was carried out with a well-documented probiotic. Thirty-two infants were enrolled, 16 in the probiotic group and 16 in the placebo group. Urine samples were collected from each subject before starting supplementation and at the end of the study period. Metabolomic profiles were obtained using a gas chromatography/mass spectrometry instrument. Subsequently, to compare groups before and after probiotic supplementation, univariate and multivariate statistical analysis were performed.

Results: In the L. reuteri treated group all metabolites for all class of nutrients (sugars, amino acids, carboxylic acids) resulted more abundant after the study period. The comparison with a control group (placebo treated), confirmed this effect on urines.

Conclusions: The metabolomic analysis of urine samples from infants treated with L. reuteri DSM 17938 allowed to detect some interesting features related to the effect of this treatment on urinary metabolome. To validate the results, a test on a larger cohort is required.

查看原文本刊更多论文

用 DSM 17938 型纽特乳酸杆菌治疗肠绞痛婴儿的尿液代谢组：一项试点随机试验。

背景：纽崔莱乳杆菌（Lactobacillus reuteri DSM 17938）是唯一被推荐用于治疗肠绞痛婴儿的益生菌，但其作用机制尚不清楚。研究目的是检测肠绞痛母乳喂养婴儿在口服沙雷氏乳杆菌 DSM 17938 或安慰剂 1 个月前后的尿液代谢指纹图谱：这项随机、盲法、安慰剂对照临床试验使用的是一种经过充分证明的益生菌。32名婴儿参加了试验，其中益生菌组和安慰剂组各16名。在开始服用补充剂之前和研究结束时，收集了每个受试者的尿液样本。使用气相色谱/质谱仪获得代谢组谱。随后，为了比较补充益生菌前后的组别，进行了单变量和多变量统计分析：结果：研究期结束后，添加了纽崔莱益生菌的研究组中所有营养物质（糖、氨基酸、羧酸）的代谢物含量都有所增加。与对照组（安慰剂治疗组）的比较证实了尿液中的这种效应：通过对使用 L. reuteri DSM 17938 治疗的婴儿尿液样本进行代谢组学分析，可以发现一些与这种治疗对尿液代谢组的影响有关的有趣特征。要验证这些结果，还需要在更大的群体中进行测试。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Minerva pediatrica PEDIATRICS-

CiteScore

2.70

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： Minerva Pediatrica publishes scientific papers on pediatrics, neonatology, adolescent medicine, child and adolescent psychiatry and pediatric surgery. Manuscripts may be submitted in the form of editorials, original articles, review articles, special articles, letters to the Editor and guidelines. The journal aims to provide its readers with papers of the highest quality and impact through a process of careful peer review and editorial work.